A Comprehensive Approach to Adherence Recovery and the Role of LAIs in Schizophrenia

Christoph U. Correll, MD, is professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital, both in New York. He is further the director of the Adverse Events Unit and the Core Laboratory Unit at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research. 

 

Professor Correll completed his medical studies at the Free University of Berlin and Dundee University Medical School in Scotland. He is a board certified general psychiatrist and child and adolescent psychiatrist, having trained at The Zucker Hillside Hospital in Queens, New York.

 

Professor Correll's research and clinical work focus on the identification, characterization and treatment of adults and youth with severe psychiatric disorders. His areas of expertise include severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders, including the prodrome, first episode, multi-episode and refractory illness phase. He further focuses on the risk-benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.

 

Professor Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of nine scientific journals. He is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.

John M. Kane, MD, is Vice President for Behavioral Health Services at North Shore University Hospital of the Long Island Jewish Heath System and he is Chairman of the Department of Psychiatry and Chief of Staff at The Zucker Hillside Hospital in Glen Oaks, New York. Dr. Kane is also a professor of psychiatry, neuroscience, and neurology and the Dr. E. Richard Feinberg Chair in Schizophrenia Research at Albert Einstein College of Medicine in New York, New York as well as Professor and Chair, Department of Psychiatry and the Department of Molecular Medicine at Hofstra North Shore-LIJ School of Medicine.

Dr. Kane is a graduate of Cornell University. He received his medical degree from New York University and completed graduate coursework at Columbia University. He completed his internship and psychiatric residency at Hillside Hospital in Glen Oaks, New York.

Dr. Kane is President of the Psychiatry Research Society, the Schizophrenia International Research Society, the Schizophrenia International Research Society, and the American Society of Clinical Psychopharmacology. He is the program co-chair of the NIMH-ASCP Annual NCDEU New Research Approaches to Mental Health Interventions meeting and a fellow of The New York Academy of Medicine, as well as a member of the board of directors of the American Society of Clinical Psychopharmacology and of the board of trustees for the Association for Research in Nervous and Mental Disease.

Dr. Kane has been a consultant for the National Institute of Mental Health and the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration, and either principle investigator or co-investigator on over 20 studies funded by the National Institute of Mental Health. He has served on the editorial boards of been a reviewer of more than 10 journals and peer-reviewed publications. Dr. Kane has authored 7 books and over 60 book chapters on psychiatry, schizophrenia, and anti-psychotic treatment and over 470 articles in psychiatric publications.